Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of September 2025. The filing details a share repurchase executed on September 10, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased: 213,147 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,480.50p; highest price paid was 1,500.00p.
- Average Price: Volume-weighted average price paid was 1,486.77p.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, the Company holds 246,366,590 ordinary shares in treasury.
- Shares in Issue: 4,069,035,137 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.05% of total voting rights.
Material Changes and Program Progress
Since the inception of the current buyback program on June 4, 2025, the Company has purchased an aggregate of 28,232,207 ordinary shares. The September 10 transaction represents a continuation of this program. There are no material changes to the Company's business operations, financial condition, or debt structure disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q2 Results for 2025.
Investor Verification Checklist
- Verify the total cumulative buyback volume (28.23 million shares) against the original program authorization limits.
- Confirm the current percentage of voting rights held in treasury (6.05%) to assess potential dilution or concentration effects.
- Review the June 4, 2025 announcement to understand the total authorized amount and duration of the non-discretionary agreement.
- Check the most recent Form 20-F or quarterly results for operational financial metrics (revenue, profit, cash flow) as they are not included in this transaction report.